

CartiMax[™]

Viable Cartilage Allograft

Introducing **CartiMax**™ Viable Cartilage Allograft for treating cartilage lesions in the knee, foot and ankle. NEW from MTF Biologics, CartiMax™ combines the clinical benefits of live, viable cartilage cells with putty-like handling properties designed to easily fill defects of different shapes and sizes.



Why CartiMax for Chondral Lesions?

Viable Chondrocytes

Characterization testing of CartiMax verifies the presence of functioning viable chondrocytes & chondrogenic growth factors.¹

Multiple studies have demonstrated that chondrocytes migrate and proliferate from the cartilage fibers and secrete components found in hyaline cartilage.²⁻⁴

Optimal Handling Properties

Unlike other solutions that may require templates, trimming, gluing, suturing or other fixation methods, CartiMax has putty-like handling properties and easily conforms to defects of different shapes and sizes.

6 Month Shelf-Life

A ready-to-go, off-the-shelf solution that demonstrates stable viability up to six months post-cryopreservation.¹

High Volume of Material

While you may need multiple packages of another scaffold to fill a 2.5cm² lesion, one package of CartiMax contains enough cartilage matrix to fill up to a 5cm² lesion. Other products may require multiple packages to fill the same volume.











Ordering Information

To order Allograft Tissue call MTF customer service at: (US) 800-433-6576 or (Global) 732-661-0202, Fax: 732-661-2298.

Processed by:
Musculoskeletal Transplant Foundation
125 May Street
Edison, New Jersey 08837
www.mtfbiologics.org

Ordering Information

Description Catalog
Number



CartiMax™ Viable Cartilage Allograft

CartiMax 401205

Data on File, MTF Biologics. Albrecht F, Roessner A, Zimmermann E. Closure of osteochondral lesions using chondral fragments and fibrin adhesive. Archives of orthopaedic and traumatic surgery Archiv fur orthopadische und Unfall-Chirurgie. 1983;101:213—7. [PubMed]. Lu Y, Dhanaraj S, Wang Z, et al. Minced cartilage without cell culture serves as an effective intraoperative cell source for cartilage repair. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2006;24:1261—70. [PubMed]. Frisbie DD, Lu Y, Kawcak CE, DiCarlo EF, Binette F, McIlwraith CW. In vivo evaluation of autologous cartilage fragment-loaded scaffolds implanted into equine articular defects and compared with autologous chondrocyte implantation. The American journal of sports medicine. 2009;37(Suppl 1):715—80S.

CONMED Corporation 525 French Road, Utica, NY 13502 Local: 727-392-6464 Toll Free: 1-800-237-0169 CONMED.com customer_service@conmed.com